- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07883577
A Study of RO7821657 in Participants With Solid Tumors
A First In-Human, Multicenter, Phase I Clinical Study of RO7821657, a Protease Activated TCB Antibody That Targets CEACAM5, in Participants With Locally Advanced and/or Metastatic Solid Tumors
The aim of this study is to characterize the safety and tolerability of RO7821657, describe its pharmacokinetics (PK), and evaluate pharmacodynamic and biomarker effects to support selection of the recommended Phase 2 dose(s) (RP2D[s])
The study consists of two parts, namely Part 1 and Part 2:
Part 1: Evaluation of RO7821657 as monotherapy in participants with microsatellite-stable (MSS) colorectal cancer (CRC).
Part 2: Evaluation of RO7821657 as monotherapy in participants with non-squamous non-small cell lung cancer (NSCLC)
Studie Overzicht
Toestand
Interventie / Behandeling
Studietype
Inschrijving (Geschat)
Fase
- Fase 1
Contacten en locaties
Studiecontact
- Naam: Fastest response: use the inquiry form. No email attachments. https://www.gene.com/contact-us/submit-medical-inquiry
Studie Contact Back-up
- Naam: Reference Study ID Number: BP46447 https://forpatients.roche.com/
- Telefoonnummer: 888-662-6728
- E-mail: global-roche-genentech-trials@gene.com
Studie Locaties
-
-
-
København Ø, Denemarken, 2100
- Werving
- Rigshospitalet
-
-
-
-
-
Sutton, Verenigd Koninkrijk, SM2 5PT
- Werving
- Royal Marsden Sutton
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Life expectancy estimated by the Investigator to be ≥12 weeks.
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1.
- Presence of measurable disease according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1; previously irradiated lesions are considered measurable if progression has been demonstrated in such lesions after the irradiation.
- Availability of archival tumor tissue or tissue obtained from a fresh biopsy at screening if formalin-fixed paraffin-embedded [FFPE]-preserved archival tissue is not available. The archival tumor tissue should come from a core biopsy, a punch biopsy, an excisional biopsy, or a surgical specimen. Lymph node biopsy, bone biopsy (unless from soft tissue), or fine needle aspiration are unacceptable for submission. Lesions that are intended to be biopsied should not be counted as target lesions.
- Adequate cardiovascular function:
New York Heart Association (NYHA) Heart Failure Class ≤ 1.
- Agreement to adhere to the contraception requirements.
Exclusion Criteria:
-
Participants with active Central Nervous System (CNS) metastases.
-
Any unresolved toxicities from prior therapy, i.e., radiotherapy, chemotherapy, targeted or checkpoint inhibitor therapy or surgical procedure, greater than CTCAE Grade 1 at the time of starting study treatment, except for alopecia and Grade 2 neuropathy.
a) Stable endocrine AEs managed with hormone replacement are permitted, including hypothyroidism on stable thyroid hormone replacement.
-
History of interstitial pulmonary disease, drug-induced pneumonitis, or evidence of active pneumonitis on screening computed tomography (CT) scan.
-
Participants with pulmonary miliary metastatic pattern (innumerable small lesions) or pulmonary lymphangitic carcinomatosis.
-
Active autoimmune disease that has required systemic treatment (except replacement treatment) within the last 2 years or any disease requiring immunosuppressive therapy while on study.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Niet-gerandomiseerd
- Interventioneel model: Sequentiële toewijzing
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Part 1A: Dose Escalation
Participants with MSS CRC will receive multiple doses of RO7821657 in single and multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Experimenteel: Part 1B: Backfill Cohorts
Participants with MSS CRC will receive RO7821657 at dosing regimen selected based on data from Part 1A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Experimenteel: Part 1C: Dose Expansion/Optimization
Participants with MSS CRC will receive RO7821657 at dosing regimens selected based on data from Parts 1A and 1B. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Experimenteel: Part 2A: Abbreviated Dose Escalation
Participants with non-squamous NSCLC will receive multiple doses of RO7821657 in multiple participant cohorts. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
|
Experimenteel: Part 2B: Dose Expansion/Optimization
Participants with non-squamous NSCLC will receive RO7821657 at dosing regimen selected based on data from Part 2A. |
Participants will receive RO7821657 as per the schedule described in the protocol. |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Part 1: Incidence and Severity of Adverse Events (AEs)
Tijdsspanne: Up to approximately 27 months
|
AEs will be graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0. Any events of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded based on the American Society for Transplantation and Cellular Therapy (ASTCT) criteria |
Up to approximately 27 months
|
|
Part 2: Incidence and Severity of Adverse Events (AEs)
Tijdsspanne: Up to approximately 27 months
|
AEs will be graded according to NCI CTCAE v5.0. Any events of CRS and ICANS will be graded based on the ASTCT criteria |
Up to approximately 27 months
|
|
Part 1A: Nature and Frequency of Dose-limiting Toxicities (DLTs)
Tijdsspanne: From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From Cycle 1 (C1) Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Part 2A: Nature and Frequency of DLTs
Tijdsspanne: From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
From C1 Day 1 to the last day in C1 (Cycle 1 = 14-35 days)
|
|
|
Parts 1A and 1B: Recommended Phase 2 Dose (RP2D) Range of RO7821657
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
|
Part 2A: RP2D Range of RO7821657
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
Secundaire uitkomstmaten
Uitkomstmaat |
Tijdsspanne |
|---|---|
|
Parts 1 and 2: Serum Concentration of RO7821657
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Objective Response Rate (ORR)
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Disease Control Rate (DCR)
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Duration of Response (DoR)
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: Progression-free Survival (PFS)
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1 and 2: PFS Rate
Tijdsspanne: At 6 months
|
At 6 months
|
|
Parts 1 and 2: Overall Survival (OS) Rate
Tijdsspanne: At 6 months
|
At 6 months
|
|
Parts 1 and 2: Correlation of Baseline Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Tumor Expression With Clinical Activity
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Part 1B: Cluster of Differentiation 8 (CD8) Expression in Tumor Tissue
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants With Presence, Frequency, Severity and Interference of Symptomatic Treatment Toxicities as Assessed by NCI Patient-reported Outcomes (PRO)-CTCAE
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Change From Baseline in Symptomatic Treatment Toxicities as Assessed by NCI PRO-CTCAE
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
|
Parts 1C and 2B: Percentage of Participants Troubled by Treatment Symptoms, as Assessed by Single Item European Organisation for Research and Treatment of Cancer Item Library 46 (EORTC IL46)
Tijdsspanne: Up to approximately 27 months
|
Up to approximately 27 months
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Studie directeur: Clinical Trials, Hoffmann-La Roche
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Andere studie-ID-nummers
- BP46447
- 2026-526150-14-00 (Ctis)
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .